Search results for "Non-invasive assessment"

showing 2 items of 2 documents

Liver Steatosis and Fibrosis in OSA patients After Long-term CPAP Treatment: A Preliminary Ultrasound Study.

2015

In cases of morbid obesity, obstructive sleep apnea (OSA) was associated with biopsy-proven liver damage. The role of non-invasive techniques to monitor liver changes during OSA treatment with continuous positive airway pressure (CPAP) is unknown. We used non-invasive ultrasound techniques to assess liver steatosis and fibrosis in severe OSA patients at diagnosis and during long-term CPAP treatment. Fifteen consecutive patients with severe OSA (apnea hypopnea index 52.5 ± 19.1/h) were studied by liver ultrasound and elastography (Fibroscan) at 6-mo (n = 3) or 1-y (n = 12) follow-up. Mean age was 49.3 ± 11.9 y, body mass index (BMI) was 35.4 ± 6.4 kg/m(2). Adherence to CPAP was ≥5 h/night. A…

Liver CirrhosisMalemedicine.medical_specialtyAcoustics and Ultrasonicsmedicine.medical_treatmentBiophysicsSettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologyBody Mass IndexTime03 medical and health sciences0302 clinical medicineFibrosisInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingObesityContinuous positive airway pressureNon-invasive assessmentUltrasonographySleep Apnea ObstructiveRadiological and Ultrasound Technologymedicine.diagnostic_testContinuous Positive Airway Pressurebusiness.industryFatty liverLiver fibrosiMiddle Agedmedicine.diseaseObstructive sleep apneanervous system diseasesrespiratory tract diseasesSurgeryObstructive sleep apneaFatty Liver030228 respiratory systemApnea–hypopnea indexLiverLiver steatosiFeasibility Studies030211 gastroenterology & hepatologyFemaleElastographyLongitudinal studySteatosisbusinessBody mass indexUltrasound in medicinebiology
researchProduct

Biochemical biomarkers of NAFLD/NASH

2020

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the Western world and the global epidemics of obesity and type 2 diabetes have led to a dramatic increase of its prevalence and incidence. Among NAFLD patients, those with nonalcoholic steatohepatitis (NASH) have a double risk of fibrosis progression, that is the main driver toward the evolution in cirrhosis and its complications, including hepatocellular carcinoma and hepatic decompensation. Furthermore, patients with NAFLD are also at risk for cardiovascular diseases and extrahepatic malignancies, that represent the first and the second cause of death, respectively. The availability of non-invasi…

medicine.medical_specialtyeducation.field_of_studyCirrhosisSteatosismedicine.diagnostic_testbusiness.industryPopulationNASHLiver fibrosiType 2 diabetesmedicine.diseaseChronic liver diseaseGastroenterologydigestive system diseasesLiver biopsyInternal medicineHepatocellular carcinomaNAFLDNonalcoholic fatty liver diseasemedicinebusinesseducationNon-invasive assessmentCause of death
researchProduct